Does the media prefer CAI or MRVI?

In the previous week, Caris Life Sciences had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for Caris Life Sciences and 3 mentions for Maravai LifeSciences. Caris Life Sciences' average media sentiment score of 0.95 beat Maravai LifeSciences' score of 0.60 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer STVN or MRVI?

Maravai LifeSciences has a consensus target price of $7.38, suggesting a potential upside of 12.60%. Given Maravai LifeSciences' higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.75 Maravai LifeSciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Does the media prefer STVN or MRVI?

In the previous week, Stevanato Group and Stevanato Group both had 3 articles in the media. Stevanato Group's average media sentiment score of 0.75 beat Maravai LifeSciences' score of 0.60 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SHC or MRVI?

In the previous week, Sotera Health had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Sotera Health and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.60 beat Sotera Health's score of 0.34 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ADPT or MRVI?

In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.60 beat Adaptive Biotechnologies' score of 0.54 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALMR or MRVI?

In the previous week, Alamar Biosciences had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 6 mentions for Alamar Biosciences and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.60 beat Alamar Biosciences' score of 0.41 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maravai LifeSciences (MRVI) Competitors

$7.07 +0.52 (+7.94%)

Closing price 04:00 PM Eastern

Extended Trading

$7.09 +0.02 (+0.28%)

As of 06:42 PM Eastern

Compare

MRVI vs. CAI, STVN, SHC, ADPT, and ALMR

Should you buy Maravai LifeSciences stock or one of its competitors? Maravai LifeSciences's main competitors and comparable companies include Caris Life Sciences (CAI), Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), and Alamar Biosciences (ALMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Maravai LifeSciences compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Caris Life Sciences has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	10.53	-$68.09M	$0.36	84.03
Maravai LifeSciences	$185.74M	9.16	-$130.77M	-$0.52	N/A

In the previous week, Caris Life Sciences had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 7 mentions for Caris Life Sciences and 3 mentions for Maravai LifeSciences. Caris Life Sciences' average media sentiment score of 0.95 beat Maravai LifeSciences' score of 0.60 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Caris Life Sciences has a net margin of 10.62% compared to Maravai LifeSciences' net margin of -37.07%. Caris Life Sciences' return on equity of 18.77% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

50.3% of Maravai LifeSciences shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Caris Life Sciences currently has a consensus price target of $27.82, indicating a potential downside of 8.04%. Maravai LifeSciences has a consensus price target of $7.38, indicating a potential upside of 12.60%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Caris Life Sciences beats Maravai LifeSciences on 13 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Stevanato Group has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Maravai LifeSciences has a consensus target price of $7.38, suggesting a potential upside of 12.60%. Given Maravai LifeSciences' higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Stevanato Group has a net margin of 10.99% compared to Maravai LifeSciences' net margin of -37.07%. Stevanato Group's return on equity of 10.43% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

50.3% of Maravai LifeSciences shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Stevanato Group has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.34	€158.21M	€0.56	34.31
Maravai LifeSciences	$185.74M	9.16	-$130.77M	-$0.52	N/A

In the previous week, Stevanato Group and Stevanato Group both had 3 articles in the media. Stevanato Group's average media sentiment score of 0.75 beat Maravai LifeSciences' score of 0.60 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Stevanato Group beats Maravai LifeSciences on 11 of the 15 factors compared between the two stocks.

How does Maravai LifeSciences compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Sotera Health presently has a consensus target price of $21.38, suggesting a potential upside of 20.56%. Maravai LifeSciences has a consensus target price of $7.38, suggesting a potential upside of 12.60%. Given Sotera Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Sotera Health is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Sotera Health has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

In the previous week, Sotera Health had 5 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Sotera Health and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.60 beat Sotera Health's score of 0.34 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sotera Health has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.35	$77.94M	$0.57	31.11
Maravai LifeSciences	$185.74M	9.16	-$130.77M	-$0.52	N/A

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sotera Health has a net margin of 13.44% compared to Maravai LifeSciences' net margin of -37.07%. Sotera Health's return on equity of 40.12% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Summary

Sotera Health beats Maravai LifeSciences on 14 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Adaptive Biotechnologies has higher revenue and earnings than Maravai LifeSciences. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	13.27	-$59.50M	-$0.41	N/A
Maravai LifeSciences	$185.74M	9.16	-$130.77M	-$0.52	N/A

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adaptive Biotechnologies has a net margin of -20.73% compared to Maravai LifeSciences' net margin of -37.07%. Maravai LifeSciences' return on equity of -15.70% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Adaptive Biotechnologies currently has a consensus price target of $30.06, suggesting a potential upside of 17.34%. Maravai LifeSciences has a consensus price target of $7.38, suggesting a potential upside of 12.60%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Adaptive Biotechnologies is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Adaptive Biotechnologies has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.60 beat Adaptive Biotechnologies' score of 0.54 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adaptive Biotechnologies beats Maravai LifeSciences on 12 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alamar Biosciences currently has a consensus target price of $31.80, suggesting a potential upside of 25.34%. Maravai LifeSciences has a consensus target price of $7.38, suggesting a potential upside of 12.60%. Given Alamar Biosciences' higher probable upside, equities analysts clearly believe Alamar Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Alamar Biosciences has higher earnings, but lower revenue than Maravai LifeSciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	23.72	-$29.82M	-$1.96	N/A
Maravai LifeSciences	$185.74M	9.16	-$130.77M	-$0.52	N/A

Alamar Biosciences has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -37.07%. Alamar Biosciences' return on equity of 0.00% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

In the previous week, Alamar Biosciences had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 6 mentions for Alamar Biosciences and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.60 beat Alamar Biosciences' score of 0.41 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alamar Biosciences beats Maravai LifeSciences on 8 of the 15 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRVI vs. The Competition

Export

Metric	Maravai LifeSciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.84B	$10.92B	$7.43B	$12.93B
Dividend Yield	N/A	1.45%	2.52%	19.59%
P/E Ratio	-13.60	32.47	274.96	25.39
Price / Sales	8.79	486.03	608.73	90.53
Price / Cash	15.60	27.31	76.68	52.75
Price / Book	4.84	6.11	10.32	6.02
Net Income	-$130.77M	$56.67B	$3.49B	$380.68M
7 Day Performance	-1.94%	-0.39%	-2.54%	-3.01%
1 Month Performance	2.76%	5.00%	-6.87%	-5.59%
1 Year Performance	109.79%	23.15%	1.81%	-5.23%

Maravai LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRVI Maravai LifeSciences	1.3266 of 5 stars	$7.07 +7.9%	$7.38 +4.3%	+102.8%	$1.84B	$208.78M	N/A	415	Gap Up
CAI Caris Life Sciences	2.5088 of 5 stars	$28.30 -6.9%	$26.50 -6.4%	N/A	$7.98B	$812.03M	78.48	1,846	News Coverage Analyst Forecast Gap Down
STVN Stevanato Group	3.5075 of 5 stars	€19.93 -0.6%	N/A	-20.6%	€6.04B	€1.34B	35.64	6,010
SHC Sotera Health	3.7582 of 5 stars	$18.46 -0.5%	$21.50 +16.5%	+10.9%	$5.27B	$1.22B	32.38	3,000	News Coverage Positive News Analyst Forecast
ADPT Adaptive Biotechnologies	3.2454 of 5 stars	$27.54 -7.7%	$28.94 +5.1%	+64.4%	$4.39B	$308.08M	N/A	624	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRVI) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Competitors

MRVI vs. CAI, STVN, SHC, ADPT, and ALMR

How does Maravai LifeSciences compare to Caris Life Sciences?

Summary

How does Maravai LifeSciences compare to Stevanato Group?

Summary

How does Maravai LifeSciences compare to Sotera Health?

Summary

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Summary

How does Maravai LifeSciences compare to Alamar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Competitors

MRVI vs. CAI, STVN, SHC, ADPT, and ALMR

How does Maravai LifeSciences compare to Caris Life Sciences?

Which has preferable earnings & valuation, CAI or MRVI?

Does the media prefer CAI or MRVI?

Which has more volatility and risk, CAI or MRVI?

Is CAI or MRVI more profitable?

Do insiders and institutionals believe in CAI or MRVI?

Do analysts rate CAI or MRVI?

Summary

How does Maravai LifeSciences compare to Stevanato Group?

Which has more risk and volatility, STVN or MRVI?

Do analysts prefer STVN or MRVI?

Is STVN or MRVI more profitable?

Do institutionals & insiders have more ownership in STVN or MRVI?

Which has preferable valuation & earnings, STVN or MRVI?

Does the media prefer STVN or MRVI?

Summary

How does Maravai LifeSciences compare to Sotera Health?

Do analysts rate SHC or MRVI?

Which has more risk and volatility, SHC or MRVI?

Does the media refer more to SHC or MRVI?

Which has stronger earnings and valuation, SHC or MRVI?

Do institutionals and insiders hold more shares of SHC or MRVI?

Is SHC or MRVI more profitable?

Summary

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Which has better valuation and earnings, ADPT or MRVI?

Do institutionals & insiders hold more shares of ADPT or MRVI?

Is ADPT or MRVI more profitable?

Do analysts recommend ADPT or MRVI?

Which has more risk & volatility, ADPT or MRVI?

Does the media refer more to ADPT or MRVI?

Summary

How does Maravai LifeSciences compare to Alamar Biosciences?

Do institutionals and insiders hold more shares of ALMR or MRVI?

Do analysts prefer ALMR or MRVI?

Which has better earnings and valuation, ALMR or MRVI?

Is ALMR or MRVI more profitable?

Does the media favor ALMR or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools